Type I interferon signaling contributes to the bias that Toll-like receptor 4 exhibits for signaling mediated by the adaptor protein TRIF

Science Signaling

Volumn 7, Issue 351, 2014, Pages

  Kolb, Joseph P ^a   Casella, Carolyn R ^a   Gupta, Shuvasree Sen ^a   Chilton, Paula M ^a   Mitchell, Thomas C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; INTERFERON; LIPID A; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; B7 ANTIGEN; BETA INTERFERON; CD86 ANTIGEN; CD86 PROTEIN, MOUSE; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MYD88 PROTEIN, MOUSE; TICAM-1 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG POTENCY; IMMUNOSTIMULATION; INFLAMMATION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOLOGY; GENE EXPRESSION REGULATION; METABOLISM;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; ANTIGENS, CD80; ANTIGENS, CD86; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION REGULATION; INFLAMMATION; INTERFERON TYPE I; INTERFERON-BETA; LIPID A; MAP KINASE KINASE 4; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84910638569     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2005442     Document Type: Article

References (71)

1. T. Kawai, O. Adachi, T. Ogawa, K. Takeda, S. Akira, Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11, 115-122 (1999).
2. M. Yamamoto, S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Sanjo, O. Takeuchi, M. Sugiyama, M. Okabe, K. Takeda, S. Akira, Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301, 640-643 (2003).
3. B. S. Park, D. H. Song, H. M. Kim, B. S. Choi, H. Lee, J. O. Lee, The structural basis of lipopolysaccharide recognition by the TLR4 - MD-2 complex. Nature 458, 1191-1195 (2009).
4. E. Latz, A. Visintin, E. Lien, K. A. Fitzgerald, T. Espevik, D. T. Golenbock, The LPS receptor generates inflammatory signals from the cell surface. J. Endotoxin Res. 9, 375-380 (2003).
5. R. Núñez Miguel, J. Wong, J. F. Westoll, H. J. Brooks, L. A. O'Neill, N. J. Gay, C. E. Bryant, T. P. Monie, A dimer of the Toll-like receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins. PLOS One 2, e788 (2007).
6. H. M. Kim, B. S. Park, J. I. Kim, S. E. Kim, J. Lee, S. C. Oh, P. Enkhbayar, N. Matsushima, H. Lee, O. J. Yoo, J. O. Lee, Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130, 906-917 (2007).
7. S. C. Lin, Y. C. Lo, H. Wu, Helical assembly in the MyD88 - IRAK4 - IRAK2 complex in TLR/IL-1R signalling. Nature 465, 885-890 (2010).
8. D. B. Conze, C. J. Wu, J. A. Thomas, A. Landstrom, J. D. Ashwell, Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and Toll-like receptormediated NF-κB activation. Mol. Cell. Biol. 28, 3538-3547 (2008).
9. S. E. Keating, G. M. Maloney, E. M. Moran, A. G. Bowie, IRAK-2 participates in multiple Toll-like receptor signaling pathways to NFkB via activation of TRAF6 ubiquitination. J. Biol. Chem. 282, 33435-33443 (2007).
10. B. Lamothe, A. Besse, A. D. Campos, W. K. Webster, H. Wu, B. G. Darnay, Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of IkB kinase activation. J. Biol. Chem. 282, 4102-4112 (2007).
11. C. Wang, L. Deng, M. Hong, G. R. Akkaraju, J. Inoue, Z. J. Chen, TAK1 is a ubiquitindependent kinase of MKK and IKK. Nature 412, 346-351 (2001).
12. J. Gohda, T. Matsumura, J. Inoue, Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β (TRIF)-dependent pathway in TLR signaling. J. Immunol. 173, 2913-2917 (2004).
13. H. Björkbacka, K. A. Fitzgerald, F. Huet, X. Li, J. A. Gregory, M. A. Lee, C. M. Ordija, N. E. Dowley, D. T. Golenbock, M. W. Freeman, The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol. Genomics 19, 319-330 (2004).
14. T. Kawai, O. Takeuchi, T. Fujita, J. Inoue, P. F. Mühlradt, S. Sato, K. Hoshino, S. Akira, Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. 167, 5887-5894 (2001).
15. I. Zanoni, R. Ostuni, L. R. Marek, S. Barresi, R. Barbalat, G. M. Barton, F. Granucci, J. C. Kagan, CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell 147, 868-880 (2011).
16. J. C. Kagan, T. Su, T. Horng, A. Chow, S. Akira, R. Medzhitov, TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-b. Nat. Immunol. 9, 361-368 (2008).
17. N. Tanimura, S. Saitoh, F. Matsumoto, S. Akashi-Takamura, K. Miyake, Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling. Biochem. Biophys. Res. Commun. 368, 94-99 (2008).
18. K. A. Fitzgerald, D. C. Rowe, B. J. Barnes, D. R. Caffrey, A. Visintin, E. Latz, B. Monks, P. M. Pitha, D. T. Golenbock, LPS-TLR4 signaling to IRF-3/7 and NF-κB involves the Toll adapters TRAM and TRIF. J. Exp. Med. 198, 1043-1055 (2003).
19. H. Häcker, V. Redecke, B. Blagoev, I. Kratchmarova, L. C. Hsu, G. G. Wang, M. P. Kamps, E. Raz, H. Wagner, G. Häcker, M. Mann, M. Karin, Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439, 204-207 (2006).
20. K.A. Fitzgerald, S.M. McWhirter, K. L. Faia, D. C. Rowe, E. Latz, D.T. Golenbock, A. J. Coyle, S. M. Liao, T. Maniatis, IKKe and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4, 491-496 (2003).
21. N. Cusson-Hermance, S. Khurana, T. H. Lee, K. A. Fitzgerald, M. A. Kelliher, Rip1 mediates the Trif-dependent Toll-like receptor 3- and 4-induced NF-κB activation but does not contribute to interferon regulatory factor 3 activation. J. Biol. Chem. 280, 36560-36566 (2005).
22. S. Sato, M. Sugiyama, M. Yamamoto, Y. Watanabe, T. Kawai, K. Takeda, S. Akira, Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) associates with TNF receptorassociated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-κB and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 171, 4304-4310 (2003).
23. T. Hirotani, M. Yamamoto, Y. Kumagai, S. Uematsu, I. Kawase, O. Takeuchi, S. Akira, Regulation of lipopolysaccharide-inducible genes by MyD88 and Toll/IL-1 domain containing adaptor inducing IFN-β. Biochem. Biophys. Res. Commun. 328, 383-392 (2005).
24. M. Yamamoto, S. Sato, H. Hemmi, S. Uematsu, K. Hoshino, T. Kaisho, O. Takeuchi, K. Takeda, S. Akira, TRAM is specifically involved in the Toll-like receptor 4 - mediated MyD88-independent signaling pathway. Nat. Immunol. 4, 1144-1150 (2003).
25. K. Hoebe, X. Du, P. Georgel, E. Janssen, K. Tabeta, S. O. Kim, J. Goode, P. Lin, N. Mann, S. Mudd, K. Crozat, S. Sovath, J. Han, B. Beutler, Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424, 743-748 (2003).
26. S. K. Gandhapudi, P. M. Chilton, T. C. Mitchell, TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion. PLOS One 8, e56855 (2013).
27. V. Mata-Haro, C. Cekic, M. Martin, P. M. Chilton, C. R. Casella, T. C. Mitchell, The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316, 1628-1632 (2007).
28. S. Sakaguchi, H. Negishi, M. Asagiri, C. Nakajima, T. Mizutani, A. Takaoka, K. Honda, T. Taniguchi, Essential role of IRF-3 in lipopolysaccharide-induced interferon-b gene expression and endotoxin shock. Biochem. Biophys. Res. Commun. 306, 860-866 (2003).
29. J. Hiscott, P. Pitha, P. Genin, H. Nguyen, C. Heylbroeck, Y. Mamane, M. Algarte, R. Lin, Triggering the interferon response: The role of IRF-3 transcription factor. J. Interferon Cytokine Res. 19, 1-13 (1999).
30. K. Hoshino, T. Kaisho, T. Iwabe, O. Takeuchi, S. Akira, Differential involvement of IFN-β in Toll-like receptor-stimulated dendritic cell activation. Int. Immunol. 14, 1225-1231 (2002).
31. K. Hoebe, E. M. Janssen, S. O. Kim, L. Alexopoulou, R. A. Flavell, J. Han, B. Beutler, Upregulation of costimulatory molecules induced by lipopolysaccharide and doublestranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat. Immunol. 4, 1223-1229 (2003).
32. +T cell response during cross-priming. J. Immunol. 176, 4682-4689 (2006).
33. P. Marrack, J. Kappler, T. Mitchell, Type I interferons keep activated T cells alive. J. Exp. Med. 189, 521-530 (1999).
34. H. Yoneyama, S. Narumi, Y. Zhang, M. Murai, M. Baggiolini, A. Lanzavecchia, T. Ichida, H. Asakura, K. Matsushima, Pivotal role of dendritic cell - derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J. Exp. Med. 195, 1257-1266 (2002).
35. W. S. Bowen, L. A. Minns, D. A. Johnson, T. C. Mitchell, M. M. Hutton, J. T. Evans, Selective TRIF-dependent signaling by a synthetic Toll-like receptor 4 agonist. Sci. Signal. 5, ra13 (2012).
36. S. M. Zughaier, S. M. Zimmer, A. Datta, R. W. Carlson, D. S. Stephens, Differential induction of the Toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins. Infect. Immun. 73, 2940-2950 (2005).
37. P. van der Ley, L. Steeghs, H. J. Hamstra, J. ten Hove, B. Zomer, L. van Alphen, Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: Influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect. Immun. 69, 5981-5990 (2001).
38. C. Cekic, C. R. Casella, C. A. Eaves, A. Matsuzawa, H. Ichijo, T. C. Mitchell, Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J. Biol. Chem. 284, 31982-31991 (2009).
39. C. A. Embry, L. Franchi, G. Nuñez, T. C. Mitchell, Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A. Sci. Signal. 4, ra28 (2011).
40. J. T. Evans, C. W. Cluff, D. A. Johnson, M. J. Lacy, D. H. Persing, J. R. Baldridge, Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines 2, 219-229 (2003).
41. J. Gaekwad, Y. Zhang, W. Zhang, J. Reeves, M. A. Wolfert, G. J. Boons, Differential induction of innate immune responses by synthetic lipid a derivatives. J. Biol. Chem. 285, 29375-29386 (2010).
42. Y. Zhang, J. Gaekwad, M. A. Wolfert, G. J. Boons, Modulation of innate immune responses with synthetic lipid A derivatives. J. Am. Chem. Soc. 129, 5200-5216 (2007).
43. A. Teghanemt, D. Zhang, E. N. Levis, J. P. Weiss, T. L. Gioannini, Molecular basis of reduced potency of underacylated endotoxins. J. Immunol. 175, 4669-4676 (2005).
44. S. Saitoh, S. Akashi, T. Yamada, N. Tanimura, M. Kobayashi, K. Konno, F. Matsumoto, K. Fukase, S. Kusumoto, Y. Nagai, Y. Kusumoto, A. Kosugi, K. Miyake, Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligandinduced TLR4 oligomerization. Int. Immunol. 16, 961-969 (2004).
45. S. Akashi, Y. Nagai, H. Ogata, M. Oikawa, K. Fukase, S. Kusumoto, K. Kawasaki, M. Nishijima, S. Hayashi, M. Kimoto, K. Miyake, Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. Int. Immunol. 13, 1595-1599 (2001).
46. H. Shen, B. M. Tesar, W. E. Walker, D. R. Goldstein, Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J. Immunol. 181, 1849-1858 (2008).
47. M. Windheim, M. Stafford, M. Peggie, P. Cohen, Interleukin-1 (IL-1) induces the Lys63-linked polyubiquitination of IL-1 receptor-associated kinase 1 to facilitate NEMO binding and the activation of Ikba kinase. Mol. Cell. Biol. 28, 1783-1791 (2008).
48. E. Chiang, O. Dang, K. Anderson, A. Matsuzawa, H. Ichijo, M. David, Cutting edge: Apoptosis-regulating signal kinase 1 is required for reactive oxygen species-mediated activation of IFN regulatory factor 3 by lipopolysaccharide. J. Immunol. 176, 5720-5724 (2006).
49. L. Navarro, M. David, p38-dependent activation of interferon regulatory factor 3 by lipopolysaccharide. J. Biol. Chem. 274, 35535-35538 (1999).
50. D. J. Wadleigh, S. T. Reddy, E. Kopp, S. Ghosh, H. R. Herschman, Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. J. Biol. Chem. 275, 6259-6266 (2000).
51. M. Lasa, K. R. Mahtani, A. Finch, G. Brewer, J. Saklatvala, A. R. Clark, Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol. Cell. Biol. 20, 4265-4274 (2000).
52. P. G. Arndt, N. Suzuki, N. J. Avdi, K. C. Malcolm, G. S. Worthen, Lipopolysaccharideinduced c-Jun NH2-terminal kinase activation in human neutrophils: Role of phosphatidylinositol 3-kinase and Syk-mediated pathways. J. Biol. Chem. 279, 10883-10891 (2004).
53. M. Yamamoto, S. Sato, K. Mori, K. Hoshino, O. Takeuchi, K. Takeda, S. Akira, Cutting edge: A novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J. Immunol. 169, 6668-6672 (2002).
54. M. Karin, The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270, 16483-16486 (1995).
55. M. G. Wathelet, C. H. Lin, B. S. Parekh, L. V. Ronco, P. M. Howley, T. Maniatis, Virus infection induces the assembly of coordinately activated transcription factors on the IFN-β enhancer in vivo. Mol. Cell 1, 507-518 (1998).
56. W. M. Chu, D. Ostertag, Z. W. Li, L. Chang, Y. Chen, Y. Hu, B. Williams, J. Perrault, M. Karin, JNK2 and IKKb are required for activating the innate response to viral infection. Immunity 11, 721-731 (1999).
57. S. Ludwig, C. Ehrhardt, E. R. Neumeier, M. Kracht, U. R. Rapp, S. Pleschka, Influenza virus-induced AP-1-dependent gene expression requires activation of the JNK signaling pathway. J. Biol. Chem. 276, 10990-10998 (2001).
58. K. E. Thomas, C. L. Galligan, R. D. Newman, E. N. Fish, S. N. Vogel, Contribution of interferon-b to the murine macrophage response to the Toll-like receptor 4 agonist, lipopolysaccharide. J. Biol. Chem. 281, 31119-31130 (2006).
59. L. C. Platanias, Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375-386 (2005).
60. N. A. de Weerd, J. P. Vivian, T. K. Nguyen, N. E. Mangan, J. A. Gould, S. J. Braniff, L. Zaker-Tabrizi, K. Y. Fung, S. C. Forster, T. Beddoe, H. H. Reid, J. Rossjohn, P. J. Hertzog, Structural basis of a unique interferon-b signaling axis mediated via the receptor IFNAR1. Nat. Immunol. 14, 901-907 (2013).
61. S. Gallucci, M. Lolkema, P. Matzinger, Natural adjuvants: Endogenous activators of dendritic cells. Nat. Med. 5, 1249-1255 (1999).
62. M. L. Santiago-Raber, R. Baccala, K. M. Haraldsson, D. Choubey, T. A. Stewart, D. H. Kono, A. N. Theofilopoulos, Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197, 777-788 (2003).
63. K. Okemoto, K. Kawasaki, K. Hanada, M. Miura, M. Nishijima, A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1b or activation of caspase-1. J. Immunol. 176, 1203-1208 (2006).
64. S. A. Luther, J. G. Cyster, Chemokines as regulators of T cell differentiation. Nat. Immunol. 2, 102-107 (2001).
65. B. E. Henricson, C. L. Manthey, P. Y. Perera, T. A. Hamilton, S. N. Vogel, Dissociation of lipopolysaccharide (LPS)-inducible gene expression in murine macrophages pretreated with smooth LPS versus monophosphoryl lipid A. Infect. Immun. 61, 2325-2333 (1993).
66. J. Meng, J. R. Drolet, B. G. Monks, D. T. Golenbock, MD-2 residues tyrosine 42, arginine 69, aspartic acid 122, and leucine 125 provide species specificity for lipid IVA. J. Biol. Chem. 285, 27935-27943 (2010).
67. C. Richez, K. Yasuda, A. A. Watkins, S. Akira, R. Lafyatis, J. M. van Seventer, I. R. Rifkin, TLR4 ligands induce IFN-α production by mouse conventional dendritic cells and human monocytes after IFN-β priming. J. Immunol. 182, 820-828 (2009).
68. M. Karaghiosoff, R. Steinborn, P. Kovarik, G. Kriegshäuser, M. Baccarini, B. Donabauer, U. Reichart, T. Kolbe, C. Bogdan, T. Leanderson, D. Levy, T. Decker, M. Müller, Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat. Immunol. 4, 471-477 (2003).
69. V. A. Rathinam, S. K. Vanaja, L. Waggoner, A. Sokolovska, C. Becker, L. M. Stuart, J. M. Leong, K. A. Fitzgerald, TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by Gram-negative bacteria. Cell 150, 606-619 (2012).
70. M. T. Orr, M. S. Duthie, H. P. Windish, E. A. Lucas, J. A. Guderian, T. E. Hudson, N. Shaverdian, J. O'Donnell, A. L. Desbien, S. G. Reed, R. N. Coler, MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant. Eur. J. Immunol. 43, 2398-2408 (2013).
71. M. B. Lutz, N. Kukutsch, A. L. Ogilvie, S. Rossner, F. Koch, N. Romani, G. Schuler, An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223, 77-92 (1999).